Immunome, Inc.

NasdaqCM:IMNM Stock Report

Market Cap: US$701.3m

Immunome Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:IMNM Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
26 Mar 25BuyUS$999,459Clay SiegallIndividual137,100US$7.29
25 Mar 25BuyUS$60,684Jean-Jacques BienaimeIndividual7,800US$7.78
24 Mar 25BuyUS$103,566Philip TsaiIndividual12,300US$8.42
24 Mar 25BuyUS$57,470Jean-Jacques BienaimeIndividual7,000US$8.21
31 Jan 25BuyUS$9,999,996Enavate SciencesCompany1,290,322US$7.75
31 Jan 25BuyUS$1,162,500Clay SiegallIndividual150,000US$7.75
22 Nov 24BuyUS$962,181Clay SiegallIndividual100,000US$9.78
21 Nov 24BuyUS$198,030Philip TsaiIndividual21,000US$9.43
21 Nov 24BuyUS$149,800Robert LechleiderIndividual15,805US$9.48
16 Aug 24BuyUS$97,608Jean-Jacques BienaimeIndividual7,000US$13.94
21 May 24BuyUS$1,388,072Clay SiegallIndividual100,000US$13.91
21 May 24BuyUS$27,140Jean-Jacques BienaimeIndividual2,000US$13.57

Insider Trading Volume

Insider Buying: IMNM insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of IMNM?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,018,2083.47%
Private Companies4,768,5835.48%
Hedge Funds5,361,1876.16%
General Public6,266,4047.2%
Institutions67,597,94677.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 45.1%.

Top Shareholders

Top 25 shareholders own 78.18% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.2%
T. Rowe Price Group, Inc.
10,624,201US$85.6m36.5%0.01%
6.51%
BlackRock, Inc.
5,662,699US$45.6m37.3%no data
6.16%
Redmile Group, LLC
5,361,187US$43.2m11%3.76%
5.48%
Enavate Sciences
4,768,583US$38.4m37.1%no data
4.95%
The Vanguard Group, Inc.
4,307,191US$34.7m43.4%no data
4.69%
EcoR1 Capital, LLC
4,079,415US$32.9m5.16%2.18%
4.47%
FMR LLC
3,892,318US$31.4m-0.69%no data
4.08%
Opaleye Management Inc.
3,550,000US$28.6m74%6.33%
3.92%
PRIMECAP Management Company
3,413,700US$27.5m1,120%0.02%
3.03%
State Street Global Advisors, Inc.
2,640,443US$21.3m24.2%no data
2.77%
Arsenal Bridge Venture II, LLC
2,414,381US$19.5m3.9%no data
2.63%
Jefferies Financial Group Inc.,Asset Management Arm
2,288,000US$18.4m14.4%0.29%
2.4%
Janus Henderson Group plc
2,088,495US$16.8m-39.6%0.01%
2%
Geode Capital Management, LLC
1,743,057US$14.0m41.8%no data
1.91%
Woodline Partners LP
1,657,729US$13.4m69%0.08%
1.85%
Marshall Wace LLP
1,610,708US$13.0m32.4%0.02%
1.58%
Susquehanna International Group, LLP, Asset Management Arm
1,377,053US$11.1m1,570%0.02%
1.23%
Michael Rapoport
1,071,172US$8.6m0%no data
0.98%
Morgan Stanley, Investment Banking and Brokerage Investments
854,598US$6.9m118%no data
0.93%
Clay Siegall
806,736US$6.5m55.3%no data
0.91%
Sofinnova Investment, Inc.
788,666US$6.4m5.6%0.49%
0.89%
Adage Capital Management, L.P.
775,000US$6.2m55%0.01%
0.89%
Point72 Asset Management, L.P.
773,720US$6.2m-0.93%0.01%
0.86%
Caption Management, LLC
750,000US$6.0m0%0.24%
0.84%
Victory Capital Management Inc.
730,785US$5.9m0%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 07:25
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunome, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael SchmidtGuggenheim Securities, LLC
Lut Ming ChengJ.P. Morgan
Wangzhi LiLadenburg Thalmann & Company